Navigation Links
NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
Date:8/5/2009

al Flu vaccine."

"The accomplishments announced today further validate our strategy to create a rapid, in-border influenza vaccine solution for governments around the world by addressing gaps in currently available vaccine technologies," added Dr. Rahul Singhvi, President and CEO of Novavax, Inc.

Novavax, Inc has successfully completed a Phase I/IIa clinical study with a candidate H5N1 influenza VLP vaccine and is currently in Phase II trials with a VLP based seasonal flu vaccine candidate. The Company plans to initiate a Phase II study with its Seasonal Flu vaccine candidate in the elderly population during Q4, 2009.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
2. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
3. Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference
4. Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate
5. Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
6. NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting
7. NOVAVAX CEO to Present at 2008 UBS Global Life Sciences Conference
8. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
9. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
10. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
11. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
(Date:1/23/2015)... MONMOUTH JUNCTION, N.J. , Jan. 23, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... surgery patients, announced the receipt of $385,642, net ... approved participant of the Technology Business Tax Certificate ...
(Date:1/23/2015)... and BOSTON , January 23, 2015 ... and development company, is delighted to announce that the ... to Miles Congreve (Vice President of Chemistry), ... Malcolm Weir (Chief Executive Officer and co-founder) for the ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4
... 24, 2011 Veridex, LLC today announced the launch ... research scientists with a fast, convenient and reliable way ... technology to capture and count CMCs, the CELLTRACKS® CMC ... engineering investigational therapies that are based on a specific ...
... Omeros Corporation (NASDAQ: OMER ) today ... Office (USPTO) of an additional patent claiming the composition ... 3 clinical development.  The patent will have a term ... extends coverage for OMS103HP and adds to our established ...
Cached Medicine Technology:Veridex Launches CELLTRACKS® Circulating Melanoma Cell Kit for Research Use 2Veridex Launches CELLTRACKS® Circulating Melanoma Cell Kit for Research Use 3Omeros Reports Allowance of Additional Patent for Arthroscopic Product 2Omeros Reports Allowance of Additional Patent for Arthroscopic Product 3
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District of ... C.R. Bard, Inc. in that proceeding’s first bellwether trial. In ... request for a new trial after finding that C.R. Bard ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... 2015 Carinsurancesavings.biz has released a new blog ... dismemberment insurance . , Purchasing an accidental death and ... advantageous. This type of rider provides benefits if the insured ... considered a lesser form of life insurance. , AD&D ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... , ... Another Group Logic Solution to Their Product Portfolio , ... (PRWEB) March 24, 2010 -- Group Logic, the ... the United Kingdom, Jigsaw Systems, is adding the MassTransit product line to its solution ...
... cases are few after time, but death risk is ... (HealthDay News) -- Breast cancer recurrence in the same ... predictor of subsequent cancer spread and death in patients ... study has found. , Researchers analyzed data from 7,749 ...
... ... questioned if the HCG diet can be harmful. Dr Robert True addresses this issue and ... ... sees patients on a daily basis that he helps lose weight through his HCG Diet program. ...
... This release is available in Spanish . ... at the link between socioeconomic status and survival after breast ... outcomes and that this is only partly explained by more ... that lower socioeconomic status is linked with women consulting their ...
... Barcelona, Spain: Many patients with metastatic breast ... treatment should be to prolong life by at least a ... best therapies, a researcher will tell the seventh European Breast ... with doctors, perception that an additional four to six months, ...
... the aches and pains that occur in old age, many ... from their past. A new study, reported in the ... ), reveals that older adults, ability to remember the past ... which the brain processes emotional content. In the older ...
Cached Medicine News:Health News:Jigsaw Systems to Deliver Group Logic's MassTransit Solution for Managed File Transfer 2Health News:Breast Cancer's Return in Original Tumor Site a Bad Sign 2Health News:HCG True Diet – Dr. Robert True Speaks About the Importance of Medical Supervision for HCG Diets 2Health News:Worse breast cancer outcomes for women from poorer backgrounds are not due to late diagnosis alone 2Health News:Worse breast cancer outcomes for women from poorer backgrounds are not due to late diagnosis alone 3Health News:What should be the goal of treatment in metastatic breast cancer? 2Health News:What should be the goal of treatment in metastatic breast cancer? 3Health News:Older adults remember the good times 2
HemoNIR™ is a portable device that measures the ability of apersons blood to carry oxygen by monitoring functional vs. non functional hemoglobin....
... real-time PCR analysis of gene expression ... LightCycler 480 System combines amazing speed ... the needs of a broad range ... including array validation, gene-knockdown studies, and ...
... Vivid 3 - Vivid family system ... level of cardiovascular performance, and offer an ... vascular, pediatrics and the OR. , ,From ... to DICOM connectivity, the new Vivid 3 ...
... Wireless, internet-based ... provides compliance and ... complete system. The ... System incorporates communication ...
Medicine Products: